9月7日，君实生物（688180/01877）发布公告，近日，公司产品重组人源化抗IL-17A单克隆抗体（代号：JS005）在治疗中重度斑块状银屑病的一项Ⅲ期临床研究中取得阳性结果，主要研究终点和关键次要终点均具有统计学显著性和临床意义的改善。公司计划近期向监管部门递交该产品的上市许可申请。
该项Ⅲ期临床研究由北京大学人民医院的张建中担任主要研究者，在全国60家研究中心共同开展。研究显示，与安慰剂相比，JS005显著改善参与者的银屑病皮损面积和严重程度，达到sPGA评分为0或1的参与者比例显著优于安慰剂。该研究结果计划在未来国际学术会议上公布。
2025年中期，君实生物实现收入11.68亿元，归母净利润-4.13亿元。
（文章来源：财中社）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.